KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA: 2011-2025

Historic EBITDA for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' EBITDA fell 247.46% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 162.33%. This contributed to the annual value of $81.7 million for FY2024, which is 1649.93% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its EBITDA stood at -$60.2 million for Q3 2025, which was down 596.10% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' EBITDA registered a high of $40.8 million during Q3 2024, and its lowest value of -$60.2 million during Q3 2025.
  • In the last 3 years, Supernus Pharmaceuticals' EBITDA had a median value of $5.2 million in 2023 and averaged $1.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 255.01% in 2023, then skyrocketed by 2,249.10% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' EBITDA stood at $6.1 million in 2021, then surged by 463.04% to $34.3 million in 2022, then tumbled by 102.90% to -$996,000 in 2023, then soared by 2,249.10% to $21.4 million in 2024, then slumped by 247.46% to -$60.2 million in 2025.
  • Its last three reported values are -$60.2 million in Q3 2025, $12.1 million for Q2 2025, and -$10.3 million during Q1 2025.